2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111315
    XEN103 840489-44-3 98%
    XEN103 is a SCD1 inhibitor, with IC50s of 14 nM and 12 nM for mSCD1 and SCD1 in HepG2 cell. XEN103 can be used for research of obesity and type 2 diabetes. XEN103 also induces sebaceous gland atrophy in mice.
    XEN103
  • HY-111321
    Fuscin 83-85-2 98%
    Fuscin, a fungal metabolite, CCR5 receptor antagonist with anti-HIV effects. Fuscin is a respiration and oxidative phosphorylation inhibitor, and also a mitochondrial SH-dependent transport-linked functions inhibitor.
    Fuscin
  • HY-111327
    Valibose 83470-79-5 98%
    Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats.
    Valibose
  • HY-111367
    MS2734 2587612-25-5 98%
    MS2734 is a inhibitor of nicotinamide N-methyltransferase (NNMT). MS2734 potently inhibits the methyltransferase activity of human NNMT (hNNMT) with an IC50 value of 14 μM. MS2734 can be used for the study of obesity, diabetes, Parkinson's disease, and various cancers with high NNMT expression.
    MS2734
  • HY-111442
    GC 14 447415-34-1 98%
    GC 14 is a selective thyroid hormone receptor antagonist, with IC50 values of 35 nM and 200 nM for hTRβ and hTRα, respectively.
    GC 14
  • HY-111487
    α-Methylacyl-CoA racemase 1 98%
    α-methylacyl-CoA racemase 1 is an enzyme that catalyzes a key chiral inversion step in the metabolism of branched-chain fatty acids, and used as a maker in prostate and other cancer.
    α-Methylacyl-CoA racemase 1
  • HY-111489
    LMPTP inhibitor 1 1908414-82-3 98%
    LMPTP inhibitor 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an IC50 of 0.8 μM LMPTP-A.
    LMPTP inhibitor 1
  • HY-111654
    Diflucortolone 2607-06-9 98%
    Diflucortolone is a fluorinated corticosteroid with fluorine atoms at the C6 and C9 positions.
    Diflucortolone
  • HY-111670
    α-Acetohydroxybutyric acid 3142-65-2 98%
    α-Acetohydroxybutyric acid is a metabolic intermediate produced under the catalysis of acetolactate synthase. α-Acetohydroxybutyric acid is generated from 2-oxobutyric acid and converted into 2,3-dihydroxy-3-methylpentanoic acid in the 2-methylbutanol biosynthetic pathway.
    α-Acetohydroxybutyric acid
  • HY-111744
    Deacetylanisomycin 27958-06-1 98%
    Deacetylanisomycin is a potent growth regulator in plants and an inactive derivative of Anisomycin. Anisomycin is a potent protein synthesis inhibitor .
    Deacetylanisomycin
  • HY-111775
    LJ570 2252488-69-8 98%
    LJ570 is a PPARα/PPARγ dual agonist with EC50s of 1.05 and 0.12 μM, respectively.
    LJ570
  • HY-111807
    Locked nucleic acid 1 206055-71-2 98%
    Locked nucleic acid 1 is a derivative of LNA-type nucleoside.
    Locked nucleic acid 1
  • HY-111918
    A71378 127902-33-4 98%
    A71378 is a selectivity CCK-A receptor agonist the IC50 values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC50 = 0.16 nM) and ileal muscle contraction (EC50 = 3.7 nM).
    A71378
  • HY-111961
    Epitizide 1764-85-8 98%
    Epitizide, a benzothiadiazine, commonly found in combination Triamterene (HY-B0575), is used to produce diuresis.
    Epitizide
  • HY-111983
    Etiroxate 17365-01-4 98%
    Etiroxate (CG-635) is a lipid lowing compound which can be used for hyperlipoproteinemia research.
    Etiroxate
  • HY-112263
    ORL1 antagonist 1 1174985-59-1 98%
    ORL1 antagonist 1 is an opioid receptor-like 1 (ORL1) antagonist with an IC50 of 61 nM.
    ORL1 antagonist 1
  • HY-112290
    MK-0736 719272-79-4 98%
    MK-0736 is a 11β-HSD type 1 (11β-HSD1) inhibitor that reduces blood pressure. MK-0736 can be used for type 2 diabetes and metabolic syndrome research.
    MK-0736
  • HY-112348
    HA-1004 hydrochloride 92564-34-6 98%
    HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models.
    HA-1004 hydrochloride
  • HY-112469
    ERK Inhibitor II (Negative control) 1177970-73-8 98%
    ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes.
    ERK Inhibitor II (Negative control)
  • HY-112488
    EXEL-0346 1239893-96-9 98%
    EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes.
    EXEL-0346
Cat. No. Product Name / Synonyms Application Reactivity